Product portfolio

Donor Screening - Nucleic Acid Testing (NAT)

Over 60 million blood and plasma donations are tested on Roche NAT systems today.

From launching the first Nucleic Acid Testing assays for blood screening, Roche has consistently remained in the forefront in keeping the blood supply safe through active surveillance of emerging infections and through rapid development of screening solutions.

Roche NAT instruments, assays and reagents have been developed using the gold standard real-time Polymerase Chain Reaction (PCR ) technology, a very sensitive and high-performing technology that detects DNA and RNA molecules of infectious agents such as HIV/HCV/HBV at an early stage of an infection. Easily integrated into pre- and post-analytic solutions they enable donor screening facilities to fully automate operations, boost throughput and achieve quicker turnaround times - leading to greater overall workflow efficiency.

Roche’s state-of-the-art NAT assays provide comprehensive genotype coverage and excellent sensitivity.  Together with analyzers that provide efficient workflows, they deliver fast results. Roche’s leading molecular diagnostic solutions deliver predictable operational outcomes for laboratories and help reduce the risk of disease transmission and adverse health effects in patients. 

Safety
Safety

Comprehensive genotype coverage – ensuring reliable detection and safe blood supply

High specificity and sensitivity - Less retesting and minimized loss of donors and donations

Efficiency
Efficiency

Automated analyzers and workflow – reducing cross contamination and providing up to 8 hours walk-away time leading to overall workflow efficiency

Data management options – for simplified order and result handling

Reliability in results
Reliability in results

Proven real-time PCR technology – ensuring reliable results

Automated sample handling solutions and user-friendly interface – reduction in manual handling errors

 

Explore Roche NAT assays and analyzers for donor screening

 

Comprehensive Nucleic Acid Testing menu for blood and plasma screening

 

  • cobas® MPX  
HIV-1 Group M, HIV-1 Group O, HIV-2, HCV and HBV
  • cobas® WNV 
West Nile virus
  • cobas® DPX
B19V and HAV
  • cobas® HEV
HEV
  • cobas® Zika
Zika virus
  • cobas® CHIKV/DENV
chikungunya virus, dengue virus
  • cobas® Babesia
Babesia parasite

 

Assays for use with the cobas s 201 system

  • cobas® TaqScreen MPX 2.0
HIV-1 Group M, HIV-1 Group O, HIV-2, HCV and HBV
  • cobas® TaqScreen WNV
West Nile virus
  • cobas® TaqScreen DPX
B19V and HAV

Note: Products of the Roche Blood Safety Solutions portfolio are not commercially available in all regions. Please contact your local Roche representative regarding availability.

 

Which NAT solution best fits your needs?
cobass 201
cobas s 201 system

Reliability meets modular automation - the first multi-dye, nucleic acid amplification technology for blood and plasma.

See more

cobas 6800 system

cobas® 6800 System

  • Mid to high volume workload
  • Throughput of up to 384 tests in an 8-hour shift - 1,536 tests in 24 hours - with only 3 user interactions per run
  • Up to 8 hours of walk-away time*
See more

* May vary based on workflow demands

cobas 8800

cobas® 8800 System

  • High to extra high volume workload
  • Throughput of up to 960 tests in an 8-hour shift - 4,032 tests in 24 hours - with only 3 user interactions per run
  • Up to 4 hours of walk-away time*
See more

* May vary based on workflow demands

 

Designed to work together

*Products of the Roche Blood Safety Solutions portfolio are not commercially available in all regions. Please contact your local Roche representative regarding availability.

References

  1. Data on file.
Nucleic Acid Testing products
Products
Category
Found 0 results in
Filters
...
    ...